Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David C Linch

Showing results (31-40 of 129) with videos related to

Pageof 13
Sort By:
Oncogene|August 31, 2002
An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemiaLouisa V Forbes, Rosemary E Gale, Arnold Pizzey, et al.
Genes, Chromosomes & Cancer|March 29, 2002
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7Stephen E Langabeer, Rosemary E Gale, Sara J Rollinson, et al.
Haematologica|May 12, 2004
No mutations in the GATA-1 gene detected in patients with acquired essential thrombocythemiaDomenica Gandini, Anthony J R Allen, Michael J Nash, et al.
British Journal of Haematology|October 5, 2006
Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF usedStuart J Ings, Carmen Balsa, David Leverett, et al.
British Journal of Haematology|November 28, 2008
Homozygous HAX1 mutations in severe congenital neutropenia patients with sporadic disease: a novel mutation in two unrelated British kindredsBradley N Smith, Phil J Ancliff, Arnold Pizzey, et al.
British Journal of Haematology|March 18, 2008
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplicationAdam J Mead, Rosemary E Gale, Panagiotis D Kottaridis, et al.
Leukemia Research|March 12, 2021
Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemiaDavid C Linch, Robert K Hills, Amanda Gilkes, et al.
Blood|April 26, 2007
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemiaAdam J Mead, David C Linch, Robert K Hills, et al.
British Journal of Haematology|March 21, 2012
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCLSally Moore, Irfan Kayani, Karl Peggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutationsClaire L Green, Kenneth K Koo, Robert K Hills, et al.
Pageof 13

Showing results (31-40 of 129) with videos related to

Sort By:
Pageof 13
Oncogene|August 31, 2002
An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemiaLouisa V Forbes, Rosemary E Gale, Arnold Pizzey, et al.
Genes, Chromosomes & Cancer|March 29, 2002
Mutations of the AML1 gene in acute myeloid leukemia of FAB types M0 and M7Stephen E Langabeer, Rosemary E Gale, Sara J Rollinson, et al.
Haematologica|May 12, 2004
No mutations in the GATA-1 gene detected in patients with acquired essential thrombocythemiaDomenica Gandini, Anthony J R Allen, Michael J Nash, et al.
British Journal of Haematology|October 5, 2006
Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF usedStuart J Ings, Carmen Balsa, David Leverett, et al.
British Journal of Haematology|November 28, 2008
Homozygous HAX1 mutations in severe congenital neutropenia patients with sporadic disease: a novel mutation in two unrelated British kindredsBradley N Smith, Phil J Ancliff, Arnold Pizzey, et al.
British Journal of Haematology|March 18, 2008
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplicationAdam J Mead, Rosemary E Gale, Panagiotis D Kottaridis, et al.
Leukemia Research|March 12, 2021
Additional impact of mutational genotype on prognostic determination in resistant and relapsed acute myeloid leukaemiaDavid C Linch, Robert K Hills, Amanda Gilkes, et al.
Blood|April 26, 2007
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemiaAdam J Mead, David C Linch, Robert K Hills, et al.
British Journal of Haematology|March 21, 2012
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCLSally Moore, Irfan Kayani, Karl Peggs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2010
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutationsClaire L Green, Kenneth K Koo, Robert K Hills, et al.
Pageof 13